Market Place
Sourcing Support
Astellas’ consolidation efforts to impact 50 Universal employees
16 Apr 2026 //
FIERCE BIOTECH
Astellas Manufacturing Chief Talks Strategy 1 Year Into Role
15 Apr 2026 //
FIERCE PHARMA
Harbinger Raises $100M; Astellas To Close Seattle Site
14 Apr 2026 //
ENDPOINTS
Evinova Secures AI Deals with Astellas, AstraZeneca
24 Feb 2026 //
FIERCE BIOTECH
Lupin Settles Mirabegron Patent Suit vs. Astellas for $90M
10 Feb 2026 //
ECONOMICTIMES
Astellas CEO Resists `Rescue BD` As Xtandi Patent Cliff Nears
15 Jan 2026 //
FIERCE BIOTECH
Astellas To Present At J.P. Morgan Healthcare Conference
06 Jan 2026 //
PR NEWSWIRE
Autobahn Labs & Astellas Partner To Speed Academic Discoveries
11 Dec 2025 //
GLOBENEWSWIRE
Ajinomoto, Astellas Enter ADC Technology Agreement
31 Oct 2025 //
PRESS RELEASE
Astellas Taps Babs Costello To Promote Izervay For GA
23 Oct 2025 //
FIERCE PHARMA
Astellas Shares Real-World VEOZAH Ph4 Data from OPTION-VMS Study
22 Oct 2025 //
PR NEWSWIRE
Enzalutamide Leads To 40% Lower Risk Of Death In Prostate Cancer
22 Oct 2025 //
INDPHARMAPOST
Astellas-Pfizer`s Combo Halves Risk of Death in Bladder Cancer
20 Oct 2025 //
FIERCE PHARMA
Astellas to Present First Real-World Veozah (fezolinetant) Data
14 Oct 2025 //
PR NEWSWIRE
Astellas To Unveil IZERVAY Data In Geographic Atrophy At AAO
08 Oct 2025 //
PR NEWSWIRE
Astellas Announces Top Management Personnel Changes
29 Sep 2025 //
CONTRACTPHARMA
Astellas Attacks Menopause Stigma with New Workplace Program
05 Sep 2025 //
FIERCE PHARMA
Pfizer, Astellas` Xtandi Combo Extends Life in Prostate Cancer
11 Jul 2025 //
FIERCE PHARMA
With Sales Turnaround, Astellas Projects Big Growth for Izervay
10 Jul 2025 //
FIERCE PHARMA
Astellas and Pfizer`s Xtandi shows long-term survival in Cancer
22 May 2025 //
PR NEWSWIRE
Astellas Presents New Data on Cancer Therapies at ASCO Meeting
19 May 2025 //
PR NEWSWIRE
Astellas to Present New Data in Geographic Atrophy
01 May 2025 //
PR NEWSWIRE
Astellas takes $760M charge, reveals slowdown for Izervay
06 Feb 2025 //
FIERCE PHARMA
Astellas Makes Announcement about Management Structure
04 Feb 2025 //
PR NEWSWIRE
Astellas Restructures Management
04 Feb 2025 //
CONTRACTPHARMA
Teva, Astellas plan to participate in IRA drug price negotiations
24 Jan 2025 //
ENDPTS
Astellas & Dr. Jen Ashton Launch Menopause Awareness Campaign
05 Dec 2024 //
PR NEWSWIRE
FDA says no to Astellas` geographic atrophy drug
19 Nov 2024 //
PHARMAPHORUM
Astellas pulls application for Izervay after talks with CHMP
29 Oct 2024 //
FIERCE PHARMA
Astellas To Present VEOZA Data At IMS World Menopause Congress
10 Oct 2024 //
PR NEWSWIRE
FDA Grants IDE For Iota Biosciences Implantable Bladder Device
10 Oct 2024 //
PR NEWSWIRE
J&J`s Erleada shows survival edge over Xtandi in real-world study
02 Oct 2024 //
FIERCE PHARMA
Astellas cruises into first DTC campaign for GA med Izervay
30 Sep 2024 //
FIERCE PHARMA
Astellas Unveils New Life Sciences Centre In US
05 Sep 2024 //
BIOSPECTRUM ASIA
Astellas Launches New Life Sciences Center in Cambridge, MA
05 Sep 2024 //
PR NEWSWIRE
Astellas to Present VEOZAH™ Data at 2024 Menopause Society Annual Meeting
04 Sep 2024 //
PR NEWSWIRE
Astellas Initiates Phase 3 Study Of Fezolinetant For VMS In Breast Cancer
27 Aug 2024 //
PR NEWSWIRE
Japan`s Astellas says employee indicted by China`s prosecutors
21 Aug 2024 //
REUTERS
CHMP Endorses New Medicines From Astellas, J&J And Ipsen
26 Jul 2024 //
FIERCE PHARMA
Astellas Gets Positive CHMP Opinion For Zolbetuximab In Gastric Cancer
26 Jul 2024 //
PR NEWSWIRE
Astellas And Osaka University Develop Stem Cell-Derived Cartilage Therapy
23 Jul 2024 //
BIOSPECTRUM ASIA
Astellas Announces Sponsored Research Agreement with UMass Chan Medical School
20 Jun 2024 //
PR NEWSWIRE
Astellas Hosts PAO Action Week To Connect Patients With Resources
10 Jun 2024 //
PR NEWSWIRE
Bayer posts pivotal data on rival to Astellas in menopause space
18 May 2024 //
FIERCE PHARMA
Astellas Showcases Oncology Portfolio At 2024 ASCO Annual Meeting
13 May 2024 //
PR NEWSWIRE
Astellas cuts a bispecific cancer & a mitochondria-focused asset Mitobridge deal
25 Apr 2024 //
ENDPTS
Astellas` XTANDI Approved in EU for Early Prostate Cancer
23 Apr 2024 //
PR NEWSWIRE
Takeda and Astellas Agree to Establish Joint Venture Company
22 Apr 2024 //
PR NEWSWIRE
CytomX Announces Nomination of Candidate in PROBODY TCB Collab with Astellas
03 Apr 2024 //
GLOBENEWSWIRE
CytomX Achieves $5M Astellas Milestone
03 Apr 2024 //
CONTRACT PHARMA
Delpharm Acquires Astellas’ Meppel Solid Dosage Production Facilities
02 Apr 2024 //
CONTRACT PHARMA
EU`s pharma legislative reforms `will scare investment away,` Astellas
01 Apr 2024 //
ENDPTS
Astellas wins approval in Japan for Claudin18.2 therapy after US rejection
27 Mar 2024 //
PRESS RELEASE
Astellas` VYLOY™ Approved in Japan for Treatment of Gastric Cancer
26 Mar 2024 //
PR NEWSWIRE
Astellas Receives Permanent J-code for IZERVAY™ for Geographic Atrophy
26 Mar 2024 //
PR NEWSWIRE
Astellas Receives +ve Opinion for XTANDI for Early Prostate Cancer Treatment
22 Mar 2024 //
PR NEWSWIRE
CytomX Announces Achievement in PROBODY® TCB Collaboration with Astellas
18 Mar 2024 //
GLOBENEWSWIRE
HPE Asset Upcycling Services Selected to Support Sustainability Commitments
14 Mar 2024 //
BUSINESSWIRE
Astellas puts the cork back in $350M Xork deal with Cartesian
14 Mar 2024 //
FIERCE BIOTECH
LabCentral and Astellas Launch Inaugural $500,000 "Diamond Ticket"
05 Mar 2024 //
PR NEWSWIRE
